Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Biden Seeks Coverage for GLP-1 RA Medications by Medicare, Medicaid
The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) obesity medications like semaglutide (Wegovy) and tirzepatide (Zepbound), challenging a two-decade-old law and facing probable opposition from the incoming Trump administration.
Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs
The Biden administration is looking to expand access to anti-obesity GLP-1 drugs like Ozempic and Wegovy for people who have Medicare and Medicaid.
Biden administration plans to expand coverage of GLP-1 drugs for Americans with Medicare & Medicaid
CNBC's Bertha Coombs joins 'Squawk on the Street' to report on Biden's administration plan to expand coverage of GLP-1 drugs for Americans with Medicare and Medicaid.
Biden proposes Medicare, Medicaid cover pricey weight-loss drugs for obese Americans
Millions of Americans could soon have access to weight-loss medications that some have called "miracle drugs."
Biden Will Move to Have Medicare, Medicaid Cover GLP-1 Weight-Loss Meds
The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and Medicaid. However, the move would have to be approved by the new Trump administration.
Should Medicare, Medicaid Cover Anti-Obesity Drugs? Doctors Speak Out
Joe Biden wants diabetes drugs that aid weight loss and treat obesity, such as Wegovy, to fall under Medicare and Medicaid.
Biden wants Medicare, Medicaid to cover pricey weight loss drugs such as Wegovy
The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.
Biden Proposes Expanded Medicare, Medicaid Coverage of Obesity Drugs
Current rules for the Medicare and Medicaid government health insurance programs cover the use of drugs such as Mounjaro, Ozempic and Wegovy for certain conditions like diabetes, but not for obesity as a condition on its own.
Biden wants drugs like Wegovy, Ozempic covered by Medicare, Medicaid
1d
GLP-1 weight-loss drugs might help protect kidneys
The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield ...
STAT
1d
Inside the telehealth-fueled GLP-1 alternative market
The new class of GLP-1 weight loss drugs have been blockbusters since they arrived on the market a few years ago. These ...
News Medical on MSN
15h
GLP-1 receptor agonists reduce kidney failure risk and cardiovascular events
Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.
1d
on MSN
Millions more Americans might get access to GLP-1 drugs
Related: Crazy-expensive weight loss drugs may soon see a major change In other news, The Biden Administration is set to ...
2d
on MSN
West Virginia residents struggle to afford GLP-1 weight loss drugs after state ends subsidy program
In 2020, West Virginia launched a pilot program to subsidize GLP-1 drugs for public employees, but the program was shuttered ...
Medscape
22h
GLP-1 Labels Don’t Reflect Trial Exclusions
Clinicians are advised to screen patients for conditions that would have rendered them ineligible to participate in the ...
1d
5 GLP-1 marketing trends as brands jump on weight loss drug craze
As use of GLP-1 weight loss drugs including Wegovy and Ozempic increases, brands are introducing new offerings.
8d
This new supplement aims to support natural GLP-1 production and gut health
Inno Supps’ Trim Biome™ GLP-1 is designed to support the body’s natural production of GLP-1 through a unique blend of ...
Medscape
1d
GLP-1 RA Drug Class Benefits People With SLE, Lupus Nephritis
The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss.
8h
The “Holiday Pause” For GLP-1s Is Quickly Approaching — but Is It Safe?
Takers of GLP-1 are reportedly going on a "holiday pause" to enjoy meal centric family celebrations. Here, an MD breaks down ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Biden
Ozempic
Food and Drug Administration
obesity
West Virginia
Feedback